Loading stock data…
NVS
$149.26+2.84 (+1.94%)
Market OpenUpdated 3:55 PM EDT
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novartis AG in the Healthcare sector is trading at $149.26. Wall Street consensus targets $153.87 (10 analysts), implying a +3.1% move over the next 12 months. The stock is currently 12% below its 52-week high of $170.46, remaining 7.7% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$149.26
Potential Downside
0%
Whystock Fair Value$149.26
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Hold
Mean target$153.87+3.1%
Range$123.00 – $180.00
Fundamentals
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart f...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
3.20%
ROE
Elite ROE. Management converts capital into profit efficiently.
35.14%
Volume
Today's trading volume
2.17M
Recent News
What's Driving Amneal's 2026 Growth Outlook?
AMRX's 2026 outlook is driven by higher profit expectations, a steady launch cadence, and growth from complex generics, injectables, and specialty brands.
Applied Digital inks hyperscaler deal, Vail Resorts cuts guidance
Yahoo Finance's Julie Hyman takes a look at some of Tuesday's trending tickers and stories, including GSK (GSK) buying biotech firm Nuvalent (NUVL), Applied Digital's (APLD) deal with a hyperscaler, and Vail Resorts (MTN) cutting its full-year guidance.
Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal
GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where the stock traded as of Monday’s close.
GSK doubles down on oncology with $10.6bn Nuvalent takeover
Nuvalent’s two late-stage lung cancer assets – zidesamtinib and neladalkib – are currently under FDA review.
How $350,000 in International Dividend Stocks Can Produce $19,000 a Year and Reduce U.S. Concentration Risk
Replacing $19,000 in annual passive income from a $350,000 portfolio requires a blended yield of roughly 5.4%. That can be difficult to achieve using only large-cap U.S. stocks, where the S&P 500 currently yields well below 2%. International companies listed on U.S. exchanges offer a larger pool of higher-yielding opportunities, making them worth consideration for ... How $350,000 in International Dividend Stocks Can Produce $19,000 a Year and Reduce U.S. Concentration Risk